德琪医药-B:2025 中期报告

香港交易所
Sep 29

牛牛AI助手已提取核心信息德琪医药2025年上半年收入为5,318万元人民币,同比下降12.5%至,主要由于希维奥®(塞利尼索)于2023年12月纳入国家医保目录后,市场需求从初期强劲增长逐渐恢复理性。期内亏损由去年同期的1.67亿元大幅收窄54.3%至7,638万元,主要受益于研发成本、销售及分销开支以及行政开支的显著减少。研发成本从去年同期的1.31亿元减少39%至7,994万元,主要由于药物...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10